Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mutiple myeloma

- PMLiVE

Takeda can’t sway NICE on oral myeloma therapy Ninlaro

Drug not recommended for NHS use in England and Wales

- PMLiVE

Janssen launches UK blood cancer awareness campaign

The pharma group join forces with designer to set up ‘giant’ names in London

- PMLiVE

NICE backs Europe’s first stem cell therapy

Holoclar is approved for routine use in patients with LSCD

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s leukaemia drug Besponsa

Firm plans to appeal the final appraisal determination on its orphan drug

- PMLiVE

NICE expands Merck KGaA’s Erbitux reach

Backs the medicines use for patients with SCCHN

- PMLiVE

Bayer’s Nexavar backed by NICE for liver cancer

The drug is the only approved first-line treatment for advanced HCC

Bayer symbol

EMA clears Bayer’s Stivarga for liver cancer

The multikinase inhibitor will treat patients with HCC

- PMLiVE

Novartis and Bayer among backers for European big data project

The IMI's BigData@Heart programme will target cardiovascular research

- PMLiVE

NICE backs Cancer Drugs Fund support for Roche’s Gazyvaro

Lymphoma treatment will be used in conjunction with chemotherapy

- PMLiVE

NICE backs Teva’s Cinqaero for severe asthma

Ruling will allow it to compete with GSK's rival IL-5 inhibitor Nucala

- PMLiVE

NICE gives green light to Ipsen’s Cabometyx

Backs the medicine’s use for patients with advanced kidney cancer

- PMLiVE

UK pharma launches legal challenge to NICE plans

Applies for judicial review of budget impact test

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links